Get the Stockscreener App
1.31
3.32%
-0.045
After Hours:
1.36
0.05
+3.82%
Alx Oncology Holdings Inc stock is traded at $1.31, with a volume of 1.17M.
It is down -3.32% in the last 24 hours and down -34.50% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.355
Open:
$1.34
24h Volume:
1.17M
Relative Volume:
0.96
Market Cap:
$181.14M
Revenue:
-
Net Income/Loss:
$-101.70M
P/E Ratio:
-0.6909
EPS:
-1.8961
Net Cash Flow:
$-84.35M
1W Performance:
-22.94%
1M Performance:
-34.50%
6M Performance:
-35.78%
1Y Performance:
-26.82%
1-Day Range:
$1.29
$1.37
1-Week Range:
$1.29
$1.72
52-Week Range:
$1.05
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
1.31 | 181.14M | 0 | -101.70M | -84.35M | -1.8961 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Mar-06-26 | Resumed | UBS | Buy |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to S&P Global BMI Index - marketscreener.com
Alx Oncology Holdings Stock Price Forecast. Should You Buy ALXO? - StockInvest.us
ALX Oncology Holdings Inc Share PriceALXO, RNS News, Articles, Quotes, & Charts (NASDAQ:ALXO) - Proactive financial news
ALXO: Lead assets advance toward phase III, with strong biomarker focus and robust financial runway - TradingView
ALX Oncology at Cantor healthcare conference: biomarker push takes center stage - Investing.com Canada
ALX Oncology at Wells Fargo conference: two drugs near key tests - Investing.com Canada
ALXO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.12 Per Share Reflects Cost DisciplineDownward Estimate Revision - dars.gov.et
ALX Oncology to Present at Upcoming Investor Conferences in September - GlobeNewswire
ALXO Q2 2026 Earnings: Narrower Quarterly Loss and EPS Beat Amid Pipeline FocusDividend Earnings Report - dars.gov.et
ALX (ALXO) Stock: Ends Up by 2.26% at $2.04 on the Day; Trading Range: the Near-Term Reference Band Stretches From $1.94 to $2.14 at the CloseMomentum Trade - vinanet.vn
ALX (ALXO) EPS and Revenue: EPS Beats Its Estimate in the Latest Session; Stock Move: Shares Close 0.96% Lower on the DayEarnings Preview - vinanet.vn
HC Wainwright Has Positive View of ALX Oncology Q3 Earnings - MarketBeat
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alx oncology CEO Jason Lettmann disposes of $4,303 in shares - Investing.com
Alx oncology CEO Jason Lettmann disposes of $4,303 in shares By Investing.com - Investing.com India
Alx Oncology SVP Shelly Wong sells $1,105 of company stock - Investing.com
ALX Oncology (NASDAQ: ALXO) CEO trims stake for taxes - Stock Titan
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALX Oncology (ALXO) SVP Finance sells shares for taxes - Stock Titan
ALXO Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 17.9% EPS SurpriseEPS Consistency Score - vinanet.vn
ALX Oncology (ALXO) Holds Near $1.96 as Biotech Stock Consolidates Below ResistanceSingle Stock ETF - dars.gov.et
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A - Stock Titan
ALXO Q2 2026 Earnings: EPS Beat of 17.92% Lifts Shares 4.15%Downward Estimate Revision - Vinanet
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALXO Q2 2026 Earnings: EPS Beats by 17.92% on Narrower Loss, But Shares Slide 6.31%EPS Miss Report - dars.gov.et
ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ALX Oncology Holdings Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
ALX Oncology (ALXO) Holds Steady at $2.10 as Shares Consolidate Near Key SupportSector Sentiment - careplusvn.com
ALX Oncology (NASDAQ:ALXO) Issues Earnings Results - MarketBeat
ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary - TradingView
ALXO: Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028 - TradingView
Is ALX Oncology Holdings Inc (ALXO) Turning a Corner After Q2 Ea - GuruFocus
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
ALX Oncology Reports Q2 2026 Net Loss of $18 Million - Quiver Quantitative
ALX Oncology reports Q2 2026 net loss of $18.0M, $153.4M cash; advances evorpacept and ALX2004 - TradingView
ALXO: Reduced net loss, robust cash position, and advancing clinical milestones drive outlook - TradingView
Clinical pipeline accelerates as ALX Oncology posts Q2 results and updates on ALX2004 study - Traders Union
ALXO Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ALX Oncology (ALXO) Projected to Post Earnings on Tuesday - MarketBeat
ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key LevelsUnusual Call Volume - dars.gov.et
ALX Oncology (ALXO) Holds Near $1.94 as Shares Dip 0.51%Risk Parity Rebalance - dars.gov.et
BlackRock, Inc. Expands Stake in ALX Oncology Holdings Inc (ALXO) with Strategic Share Purchase - GuruFocus
ALXO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Redmile Group LLC Acquires 4,699,470 Shares of ALX Oncology Holdings Inc. $ALXO - MarketBeat
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC - MarketBeat
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
ALX Oncology Holdings Inc (ALXO) Cash Flow - TradingKey
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):